XEN Glaucoma Implant With Mitomycin C 1-Year Follow-up: Result and Complications
Galal A, Bilgic A, Eltanamly R, Osman A J Ophthalmol. 2017;2017:5457246
Study Summary
Galal and colleagues performed a prospective interventional study in 13 eyes of 10 patients with primary open-angle glaucoma to evaluate a gel microstent (XEN®; AqueSys, Inc).
Inclusion criteria required that patients had uncontrolled intraocular pressure (IOP), were intolerant to therapy, or were on maximal therapy but undergoing cataract extraction. XEN implantation was performed by one surgeon, and all patients were treated with subconjunctival mitomycin C. Of the 13 eyes, three were pseudophakic and 10 underwent simultaneous phacoemulsification.
Patients were followed for 1 year after surgery, with evaluation of IOP, number of medications, vision, and complications.
IOP reduction ≥ 20% from preoperative baseline at 1 year without any glaucoma medications was defined as complete success; partial success was defined as IOP reduction of ≥ 20% at 1 year with medications. Complete success was achieved in 42% of eyes and 66% qualified success. After 1 year, IOP decreased from 16 ± 4 mm Hg at baseline to 12 ± 3 mm Hg. The number of medications decreased from a mean of 1.9 ± 1 at baseline to 0.3 ± 0.49.
Complications included implant extrusion in one eye and choroidal detachment in two eyes, and two eyes required
